$3.25
3.50% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US2312692005
Symbol
CRIS
Sector
Industry

Curis, Inc. Stock price

$3.25
-1.20 26.97% 1M
-4.20 56.38% 6M
-9.50 74.51% YTD
-10.85 76.95% 1Y
-96.75 96.75% 3Y
-27.75 89.52% 5Y
-122.75 97.42% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.11 3.50%
ISIN
US2312692005
Symbol
CRIS
Sector
Industry

Key metrics

Market capitalization $27.52m
Enterprise Value $45.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.48
P/S ratio (TTM) P/S ratio 2.68
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 0.44%
Revenue (TTM) Revenue $10.26m
EBIT (operating result TTM) EBIT $-47.75m
Free Cash Flow (TTM) Free Cash Flow $-40.49m
Cash position $20.85m
EPS (TTM) EPS $-7.81
P/E forward negative
P/S forward 2.86
EV/Sales forward 4.76
Short interest 2.28%
Show more

Is Curis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Curis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Curis, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Curis, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Curis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
0% 0%
100%
- Direct Costs 0.74 0.74
50% 50%
7%
9.52 9.52
9% 9%
93%
- Selling and Administrative Expenses 17 17
10% 10%
167%
- Research and Development Expense 40 40
3% 3%
386%
-47 -47
5% 5%
-459%
- Depreciation and Amortization 0.61 0.61
52% 52%
6%
EBIT (Operating Income) EBIT -48 -48
3% 3%
-465%
Net Profit -45 -45
3% 3%
-443%

In millions USD.

Don't miss a Thing! We will send you all news about Curis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Curis, Inc. Stock News

Neutral
PRNewsWire
19 days ago
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
Neutral
Seeking Alpha
about one month ago
Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Opera...
Neutral
PRNewsWire
about one month ago
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
More Curis, Inc. News

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Head office United States
CEO James Dentzer
Employees 49
Founded 2000
Website www.curis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today